Last year, Viatris Inc generated 9.18B USD for its biggest-performing segment, Brands. The United States made the largest contribution, accounting for 3.01B USD last year. For the latest quarter, Viatris Inc reported the revenue of 2.42B USD for the period ending 2026-06-30, which came from the top-performing segment, Brands. Developed markets contributed the highest revenue, at 2.19B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Brands

Generics

Complex Gx an dBiosimilars

Central Nervous System and Anesthesia

Respiratory Allergy

Infectious Disease

Gastroenterology

Oncology

Cardiovascular

Diabetes & Metabolism

Other Therapeutic Franchises

Womens Healthcare

Dermatology

Immunology

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Brands

9.18B(64.45%)

9.20B(62.62%)

9.80B(63.69%)

9.89B(60.98%)

10.84B(60.86%)

5.23B(44.29%)

--(--)

Generics

5.07B(35.55%)

5.49B(37.38%)

5.59B(36.31%)

5.02B(30.92%)

5.63B(31.61%)

5.29B(44.75%)

--(--)

Complex Gx an dBiosimilars

--(--)

1.31B(8.10%)

1.34B(7.53%)

1.30B(10.96%)

--(--)

Central Nervous System and Anesthesia

--(--)

1.82B(15.98%)

1.94B(17.19%)

Respiratory Allergy

--(--)

1.80B(15.87%)

1.25B(11.11%)

Infectious Disease

--(--)

1.65B(14.53%)

1.53B(13.57%)

Gastroenterology

--(--)

1.14B(10.02%)

1.12B(9.90%)

Oncology

--(--)

1.05B(9.22%)

758.90M(6.73%)

Cardiovascular

--(--)

887.50M(7.81%)

1.08B(9.59%)

Diabetes & Metabolism

--(--)

831.90M(7.32%)

790.10M(7.01%)

Other Therapeutic Franchises

--(--)

783.20M(6.89%)

1.21B(10.76%)

Womens Healthcare

--(--)

714.70M(6.29%)

708.30M(6.29%)

Dermatology

--(--)

541.00M(4.76%)

778.60M(6.91%)

Immunology

--(--)

150.60M(1.32%)

106.80M(0.95%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

China (Country)

Developed markets

Emerging Markets

Greater China

JANZ

India

France

Other countries

Northern America

Europe

The Netherlands

Europe - Other

Northern America - Other

Asia

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

3.01B(59.11%)

3.43B(17.14%)

--(--)

3.75B(62.72%)

3.97B(64.13%)

3.87B(63.13%)

4.68B(22.31%)

5.39B(27.20%)

4.85B(51.79%)

4.43B(57.87%)

3.87B(56.40%)

3.89B(57.68%)

3.24B(53.11%)

China (Country)

2.08B(40.89%)

1.91B(9.54%)

--(--)

Developed markets

--(--)

8.93B(44.56%)

9.25B(60.12%)

9.77B(60.23%)

10.43B(58.54%)

--(--)

Emerging Markets

--(--)

2.25B(11.23%)

2.55B(16.58%)

2.62B(16.13%)

3.14B(17.65%)

--(--)

Greater China

--(--)

2.17B(10.81%)

2.16B(14.04%)

2.20B(13.57%)

2.21B(12.42%)

--(--)

JANZ

--(--)

1.35B(6.72%)

1.42B(9.26%)

1.63B(10.07%)

2.03B(11.38%)

--(--)

India

--(--)

1.16B(19.35%)

1.17B(18.94%)

1.16B(19.02%)

1.08B(5.16%)

985.80M(4.98%)

--(--)

France

--(--)

1.07B(17.93%)

1.05B(16.94%)

1.09B(17.85%)

--(--)

Other countries

--(--)

5.88B(27.98%)

4.51B(22.76%)

2.06B(21.97%)

1.62B(21.20%)

--(--)

Northern America

--(--)

5.13B(24.43%)

5.76B(29.10%)

--(--)

Europe

--(--)

4.11B(19.56%)

3.07B(15.52%)

--(--)

1.48B(19.31%)

1.43B(20.85%)

1.30B(19.22%)

1.78B(29.17%)

The Netherlands

--(--)

117.50M(0.56%)

88.30M(0.45%)

66.50M(0.71%)

--(--)

Europe - Other

--(--)

2.14B(22.85%)

--(--)

Northern America - Other

--(--)

251.50M(2.69%)

123.10M(1.61%)

121.50M(1.77%)

167.30M(2.48%)

206.90M(3.39%)

Asia

--(--)

1.44B(20.98%)

1.39B(20.62%)

875.21M(14.33%)